drugset / Trial / NCT05603039
A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a phase Ib/II trial to evaluate the safety, pharmacokinetics and preliminary efficacy of QL1706 or QL1604 combined with bevacizumab in patients with advanced hepatocellular carcinoma.
Timeline
- Start
- 2021-07-01
- Primary completion
- 2023-12-30
- Completion
- 2023-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | QL1604 | Monoclonal antibody | 200 mg | Intravenous |
| Subject | QL1706 | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | QL1706 | Monoclonal antibody | 7.5 mg/kg | Intravenous |